stockrow
Saturday 7 November 2026
Export REVB’s income statement to Excel — free account
Revelation Biosciences, Inc.
REVB Healthcare Biotechnology
- EPS
- +96.9%
- Free cash flow
- −35.3%
Quarter to June 2026, against a year earlier
3.70
0.14
+3.93%
Follow REVB
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
5.41 | 3.43 | 2.18 | 1.22 | 0.89 | 0.19 | 0.86 | — |
Net Debt/EBITDA |
1.18 | 0.82 | 1.39 | 0.48 | 0.11 | 3.69 | 0.00 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.56 | 1.22 | 60.57 | 1.04 | 0.93 | 0.13 | 0.00 | — |
Capex/Depreciation |
0.00 | (0.69) | 0.00 | 0.00 | (7.86) | — | — | — |
| (219.10%) | (264.85%) | (3.12%) | (2,272.74%) | 413.94% | 57.25% | (0.01%) | — | |
| (163.31%) | (159.69%) | (1.36%) | (287.04%) | (31.46%) | (4.40%) | (31.72%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(168.32%) | (319.40%) | (1.81%) | (1,029.04%) | 10,477.97% | 58.60% | 100.00% | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Free Cash Flow per Share |
(93.23) | (9,170.25) | (36,431.50) | (112,194.00) | 0.00 | (0.09) | 0.00 | — |
Cash per Share |
120.63 | 3,249.50 | 59,958.50 | 52,530.00 | 0.00 | 0.22 | 0.00 | — |
Shareholders Equity per Share |
99.90 | 2,354.20 | 33,238.50 | 10,525.00 | 0.00 | (2.36) | (0.01) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
99.90 | 2,354.20 | 33,238.50 | 10,525.00 | 0.00 | (2.36) | (0.01) | — |
Free Cash Flow |
(8.27) | (18.34) | (7.29) | (11.22) | (11.22) | (0.22) | — | — |
Working Capital |
8.81 | 4.65 | 6.58 | 0.96 | (0.23) | (2.78) | 0.00 | — |
Capital Expenditures |
— | (0.02) | — | — | (0.13) | — | — | — |
Net Current Asset Value |
8.09 | 4.65 | 6.58 | 0.96 | (0.23) | (79.20) | 0.00 | — |
| Other line items | ||||||||
Quick Ratio |
5.36 | 3.40 | 2.15 | 1.18 | 0.60 | 0.16 | 0.00 | — |
Depreciation/Fixed assets |
1.50 | 0.50 | 0.38 | 0.28 | 0.15 | — | — | — |
Cash ROIC |
(42.28%) | (163.65%) | (39.09%) | (177.93%) | (954.95%) | 4.20% | 0.00% | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(93.23) | (9,160.65) | (36,431.50) | (112,194.00) | 0.00 | (0.09) | 0.00 | — |
Capex per Share |
0.00 | (9.60) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Payables |
0.68 | 1.07 | 0.96 | 0.58 | 0.32 | 0.03 | 0.03 | — |
Average Assets |
9.10 | 9.42 | 8.86 | 3.77 | 38.10 | 37.09 | 0.01 | — |
Average Common Equity |
6.78 | 5.68 | 3.85 | 0.48 | (2.90) | (2.85) | 33.91 | — |
Capex to Sales |
— | 0.00 | — | — | 0.00 | — | — | — |
Columns are period end dates · fundamentals updated 2 Nov 2026